PLoS ONE (Jan 2010)

Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence.

  • Pierre Perrot,
  • Julie Rousseau,
  • Anne-Laure Bouffaut,
  • Françoise Rédini,
  • Elisabeth Cassagnau,
  • Frédéric Deschaseaux,
  • Marie-Françoise Heymann,
  • Dominique Heymann,
  • Franck Duteille,
  • Valérie Trichet,
  • François Gouin

DOI
https://doi.org/10.1371/journal.pone.0010999
Journal volume & issue
Vol. 5, no. 6
p. e10999

Abstract

Read online

BACKGROUND: Osteosarcoma is the most common malignant primary bone tumour in young adult treated by neo adjuvant chemotherapy, surgical tumor removal and adjuvant multidrug chemotherapy. For correction of soft tissue defect consecutive to surgery and/or tumor treatment, autologous fat graft has been proposed in plastic and reconstructive surgery. PRINCIPAL FINDINGS: We report here a case of a late local recurrence of osteosarcoma which occurred 13 years after the initial pathology and 18 months after a lipofilling procedure. Because such recurrence was highly unexpected, we investigated the possible relationship of tumor growth with fat injections and with mesenchymal stem/stromal cell like cells which are largely found in fatty tissue. Results obtained in osteosarcoma pre-clinical models show that fat grafts or progenitor cells promoted tumor growth. SIGNIFICANCE: These observations and results raise the question of whether autologous fat grafting is a safe reconstructive procedure in a known post neoplasic context.